Korro Bio Statistics
Total Valuation
Korro Bio has a market cap or net worth of $114.09 million. The enterprise value is $56.26 million.
Important Dates
The last earnings date was Thursday, March 12, 2026, after market close.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 9.92 million shares outstanding. The number of shares has increased by 18.78% in one year.
| Current Share Class | 9.92M |
| Shares Outstanding | 9.92M |
| Shares Change (YoY) | +18.78% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 5.85% |
| Owned by Institutions (%) | 51.84% |
| Float | 6.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.48 |
| Forward PS | 56.78 |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.71, with a Debt / Equity ratio of 0.45.
| Current Ratio | 6.71 |
| Quick Ratio | 6.37 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.46% and return on invested capital (ROIC) is -32.35%.
| Return on Equity (ROE) | -63.46% |
| Return on Assets (ROA) | -29.16% |
| Return on Invested Capital (ROIC) | -32.35% |
| Return on Capital Employed (ROCE) | -64.32% |
| Weighted Average Cost of Capital (WACC) | 13.09% |
| Revenue Per Employee | $84,724 |
| Profits Per Employee | -$1.02M |
| Employee Count | 87 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $104,000 in taxes.
| Income Tax | 104,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.39% in the last 52 weeks. The beta is 2.54, so Korro Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.54 |
| 52-Week Price Change | -45.39% |
| 50-Day Moving Average | 10.82 |
| 200-Day Moving Average | 18.74 |
| Relative Strength Index (RSI) | 50.28 |
| Average Volume (20 Days) | 188,290 |
Short Selling Information
The latest short interest is 1.04 million, so 10.51% of the outstanding shares have been sold short.
| Short Interest | 1.04M |
| Short Previous Month | 1.07M |
| Short % of Shares Out | 10.51% |
| Short % of Float | 16.01% |
| Short Ratio (days to cover) | 4.05 |
Income Statement
In the last 12 months, Korro Bio had revenue of $7.37 million and -$88.42 million in losses. Loss per share was -$9.42.
| Revenue | 7.37M |
| Gross Profit | 46,000 |
| Operating Income | -94.50M |
| Pretax Income | -88.31M |
| Net Income | -88.42M |
| EBITDA | -89.62M |
| EBIT | -94.50M |
| Loss Per Share | -$9.42 |
Full Income StatementBalance Sheet
The company has $92.48 million in cash and $44.67 million in debt, with a net cash position of $57.83 million or $5.83 per share.
| Cash & Cash Equivalents | 92.48M |
| Total Debt | 44.67M |
| Net Cash | 57.83M |
| Net Cash Per Share | $5.83 |
| Equity (Book Value) | 99.03M |
| Book Value Per Share | 10.54 |
| Working Capital | 83.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$68.35 million and capital expenditures -$1.89 million, giving a free cash flow of -$70.24 million.
| Operating Cash Flow | -68.35M |
| Capital Expenditures | -1.89M |
| Free Cash Flow | -70.24M |
| FCF Per Share | -$7.08 |
Full Cash Flow StatementMargins
| Gross Margin | 0.62% |
| Operating Margin | -1,282.04% |
| Pretax Margin | -1,198.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.78% |
| Shareholder Yield | -18.78% |
| Earnings Yield | -77.50% |
| FCF Yield | -61.57% |
Analyst Forecast
The average price target for Korro Bio is $47.10, which is 309.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.10 |
| Price Target Difference | 309.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 57.30% |
| EPS Growth Forecast (5Y) | 6.55% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korro Bio has an Altman Z-Score of -1.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.5 |
| Piotroski F-Score | 1 |
